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Abstract
Background Gastric cancer (GC) is histologically a very heterogeneous disease, and the temporal development of different 
histological phenotypes remains unclear. Recent studies in lung and ovarian cancer suggest that KRAS activation (KRAS-
act) can influence histological phenotype. KRASact likely results from KRAS mutation (KRASmut) or KRAS amplification 
(KRASamp). The aim of the study was to investigate whether KRASmut and/or KRASamp are related to the histological 
phenotype in GC.
Methods Digitized haematoxylin/eosin-stained slides from 1282 GC resection specimens were classified according to Japa-
nese Gastric Cancer Association (JGCA) and the Lauren classification by at least two observers. The relationship between 
KRAS status, predominant histological phenotype and clinicopathological variables was assessed.
Results KRASmut and KRASamp were found in 68 (5%) and 47 (7%) GCs, respectively. Within the KRASmut and KRASamp 
cases, the most frequent GC histological phenotype was moderately differentiated tubular 2 (tub2) type (KRASmut: n = 27, 
40%; KRASamp: n = 21, 46%) or intestinal type (KRASmut: n = 41, 61%; KRASamp: n = 23, 50%). Comparing individual 
histological subtypes, mucinous carcinoma displayed the highest frequency of KRASmut (JGCA: n = 6, 12%, p = 0.012; 
Lauren: n = 6, 12%, p = 0.013), and KRASamp was more frequently found in poorly differentiated solid type (n = 12, 10%, 
p = 0.267) or indeterminate type (n = 12, 10%, p = 0.480) GC. 724 GCs (57%) had intratumour morphological heterogeneity.
Conclusions This is the largest GC study investigating KRAS status and histological phenotype. We identified a relation-
ship between KRASmut and mucinous phenotype. The high level of intratumour morphological heterogeneity could reflect 
KRASmut heterogeneity, which may explain the failure of anti-EGFR therapy in GC.
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Introduction
Gastric cancer (GC) is histologically a very heterogeneous 
disease, and this is reflected in the numerous proposed 
histological classification schemes [1]. The temporal 
development of different histological phenotypes in GC 
remains unclear. Recent studies suggest that Kirsten Rat 
Sarcoma Viral Oncogene Homolog (KRAS) activation and 
downstream signalling can impact on the properties and 
functions of the tumour microenvironment [2], and thus 
may influence histological phenotype. Likely mechanisms 
of KRAS activation include KRAS mutation (KRASmut) 
and KRAS amplification (KRASamp) [3].
Mutations in KRAS have been identified in many human 
cancers and result in the constitutive activation of KRAS 
and the receptor tyrosine kinase (RTK) pathway [4]. The 
frequency of KRASmut is variable across different can-
cer types, with the highest frequency in pancreatic cancer 
(90%) followed by colon (34.6%), lung (16.5%) and ovar-
ian (11%) cancer and the lowest frequencies in cervical 
(6.6%), prostate (5%) and oesophageal cancer (2%) [5]. In 
a review of the literature we identified, on average, only 
6.5% of GC have a KRASmut [6]. In colorectal cancer, 
routine testing for KRASmut is now implemented as a pre-
dictor of response to anti-epidermal growth factor receptor 
(EGFR) therapy [7].
Several studies have demonstrated a relationship 
between KRASmut status and histological phenotype in 
lung and ovarian cancer. In the subgroup of invasive muci-
nous adenocarcinoma of the lung, KRAS is mutated in up 
to 86% of cases [8]. In ovarian cancer, KRASmut has been 
identified in almost all cases with a mucinous histological 
phenotype [9]. The relationship between KRASmut status 
and histological phenotype in GC remains to be clarified 
[6].
The reported frequency of KRASamp is 1–9% in GC 
[10–16]. There are no reports of a relationship between 
KRAS DNA copy number and histological phenotype in 
other cancer types and in GC it has not been investigated in 
a large study. There is increasing recognition of the clini-
cal importance of KRASamp in GC. KRASamp is also asso-
ciated with a worse survival [3, 10, 12], whereas KRASmut 
do not appear to influence survival of GC patients [17].
Recently, image analysis on lung cancer haematoxy-
lin and eosin (H&E) stained sections using deep learning 
was predictive of mutation status [18], thus suggesting 
that morphological phenotype is reflective of molecular 
phenotype. Investigating the relationship between KRAS 
activation by KRASmut and/or KRASamp and histologi-
cal phenotype may provide some insight into gastric ade-
noma–carcinoma sequence progression and the origin of 
histological heterogeneity. Based on the studies in lung 
and ovarian cancer, we hypothesise that KRAS activation 
influences histological phenotype and is associated with a 
mucinous phenotype in GC. This would suggest that KRAS 
activation is an early event in GC, occurring before the 
phenotype is determined.
The aim of this multicentre GC study was to investigate 
the relationship of KRAS activation status (KRASmut and/or 
KRASamp) with the histological phenotype in a large series 
of GCs from UK, Japan and The Cancer Genome Atlas 
(TCGA). In addition, the relationship between KRAS sta-
tus, clinicopathological variables, survival and microsatellite 
instability status was assessed.
Material and methods
Patients
Kanagawa Cancer Center Hospital (KCCH), Yokohama, Japan
This cohort included 250 patients with TNM stage II/III GC 
who underwent potentially curative surgery at Kanagawa 
Cancer Center Hospital (Yokohama, Japan) between 2001 
and 2010. One hundred and six (43%) patients were treated 
with surgery alone, 108 (43%), 22 (9%), 14 (6%) patients 
received S-1, tegafur–uracil or S-1 combined with other 
cytotoxic drug therapy, respectively. Demographical, clinical 
and pathological data were retrieved from hospital records. 
The study was approved by the Local Research Ethics 
Committee.
Leeds Teaching Hospitals NHS Trust (LTHT), Leeds, UK
This cohort included 277 patients with GC who underwent 
potentially curative surgery at the Department of Surgery, 
Leeds General Infirmary (Leeds, UK), between 1970 and 
2004. Seven (3%) patients were treated by chemotherapy 
followed by surgery and the remaining 270 (98%) by surgery 
alone. Clinical and pathological data were retrieved from 
histopathology reports, electronic patient hospital records 
and the Northern and Yorkshire Cancer Registry. The study 
was approved by the Local Research Ethics Committee 
(LREC no. CA01/122).
The Cancer Genome Atlas
The TCGA stomach adenocarcinoma (STAD) clinicopatho-
logical and molecular dataset of 295 patients was obtained 
from the publically available TCGA database portal [19].
Tokyo Metropolitan Geriatric Hospital and Institute 
of Gerontology (TMGH), Tokyo, Japan
This cohort included 420 patients with 460 GC who were 
treated by surgery in the Tokyo Metropolitan Geriatric 
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Hospital between 2000 and 2008. Three hundred and eighty 
patients had single carcinoma, and 36 had 2 or more carcino-
mas. Patients with Lynch syndrome were excluded from the 
current study. None of the patients underwent neoadjuvant 
chemotherapy. Histopathological examination and medi-
cal research were performed with informed written consent 
by the patients, and this work was approved by the ethics 
committee of the Tokyo Metropolitan Geriatric Hospital 
(#230,225, R16-23).
Histopathological classification
pT and pN stages were reported according to 7th edition of 
the UICC TNM classification for GC [20].
In all cohorts, H&E  stained formalin fixed paraffin 
embedded (FFPE) tissue sections from the resection speci-
mens were reviewed. In the KCCH and LTHT cohorts, 
H&E stained slides were scanned at 40 × magnification 
using an Aperio AT2 scanner for review. In the TCGA 
cohort, H&E stained slides were viewed online using the 
cancer digital slide archive (https ://cance r.digit alsli dearc 
hive.net/). In the TMGH cohort, classification was per-
formed using the glass slides.
Histological classification according to JGCA scheme 
was performed [21]. Mucinous carcinoma were defined as 
tumour cells located in mucinous pools comprising an area 
greater than 50% of the total tumour. GC were classified as 
signet-ring cell carcinoma when signet-ring cells were pre-
sent in more than 50% of the tumour volume. In cases where 
more than one histological phenotype was identified, the 
most predominant phenotype was recorded, and these GCs 
were categorised as heterogeneous. JGCA classification was 
converted to Lauren classification [22] according to Table 1. 
As there is no Lauren classification for mucinous GC, we 
retained mucinous carcinomas as a separate category to dis-
tinguish them from other histological types.
DNA extraction
The area with the highest tumour cell density was identi-
fied on H&E stained sections and the whole tumour area, 
irrespective of subregions with different histological pheno-
types was microdissected after staining with Shandon instant 
haematoxylin (Thermo Scientific, Cheshire, UK) using 
a sterile surgical blade. Tumour DNA from FFPE mate-
rial was extracted from KCCH and LTHT GCs using the 
QIAmp DNA Micro Kit (Qiagen, Hilden, Germany) as pre-
viously described [23]. DNA concentration was measured 
by ND-100 Spectrophotometer (Labtech International) and 
samples were diluted using Tris-EDTA buffer. In the TMGH 
cohort, DNA was extracted using a phenol–chloroform pro-
cedure as described previously [24].
KRAS gene copy number and data analyses
KRAS copy number status was investigated in KCCH, LTHT 
and TCGA cohorts.
In the KCCH and LTHT cohort, KRAS gene copy num-
ber was determined by multiplex ligation-dependent probe 
amplification (MLPA) using the Salsa-FAM-labeled MLPA 
reagent kit and probemix P458-A1 or the updated version 
-B1 (MRC Holland, Amsterdam, The Netherlands) as previ-
ously described [25]. For further details on the KRAS probes 
included in this probemix see Supplementary Table 1. Frag-
ment analysis of the MLPA reaction product was performed 
using capillary electrophoresis ABI-3130 XL (Applied 
Biosystems, California, USA) as previously described [25]. 
Failed experiments were repeated at least twice before a case 
was finally excluded from the analyses.
KRAS DNA copy number data from 237 KCCH GC has 
been previously published [25], but was re-analysed using 
a different methodology in the current study. The output 
files (FSA files) from the sequencer were initially imported 
into Coffalyser.net for fragment analysis and results were 
exported as csv files. Subsequent analyses were performed 
using the MLPAInter method, as previously described [26], 
implemented in R. Samples were normalised per batch using 
reference samples processed in each batch. Quality control 
was performed to exclude samples with low overall intensity, 
with a large difference in intensity between short probes and 
long probes, with low intensity of denaturation controls, or 
high within gene variation, defined as the average of the 
standard deviation of log-transformed values. Final values 
were calculated by averaging the peak height of each probe 
Table 1  Japanese Gastric Cancer Association histological classifica-
tion of common types of gastric cancers in relation to Lauren clas-
sification
Table created after personal communication with H. Grabsch, March 
12, 2019
Histological classification
Lauren Japanese Gastric Cancer Association (JGCA)
Intestinal Differentiated:
 Papillary adenocarcinoma (pap)
 Tubular adenocarcinoma (tub)
  Well-differentiated (tub1)
  Moderately differentiated (tub2)
Diffuse Undifferentiated:
 Poorly differentiated adenocarcinoma (por)
  Non-solid type (por2)
 Signet-ring carcinoma (sig)
Mucinous Differentiated/undifferentiated:
 Mucinous adenocarcinoma (muc)
Indeterminate Undifferentiated:
 Poorly differentiated adenocarcinoma (por)
  Solid type (por1)
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and then averaging the results of replicates. Copy number 
thresholds were set based on previously published studies 
[25, 27, 28], with a DNA copy number > 1.31 categorised 
as amplification. This analysis was performed separately for 
KCCH and LTHT cohorts.
In TCGA, KRASamp were determined by array-based 
somatic copy number analysis [29]. Level 3 copy number 
segmentation data was downloaded from the TCGA data 
portal [19] and used to estimate copy number for KRAS. 
Based on previous studies, a LogRatio > 0.4 was categorised 
as amplification [30].
KRAS mutation status
KRASmut data from a previous study were available for 230 
KCCH and 275 LTHT GC patients [17]. KRASmut testing 
was performed on an additional 12 KCCH GCs as previ-
ously described [17]. In TCGA, KRASmut status was deter-
mined by whole-exome sequencing [29] and results were 
downloaded from the TCGA database portal [19] for 289 
patients. In the TMGH cohort, KRAS (codon 12 and 13) 
was examined by polymerase chain reaction-restriction frag-
ment length polymorphism (PCR-RFLP), using primers and 
methods previously described [31, 32].
Microsatellite instability (MSI) status
Immunohistochemistry of DNA mismatch repair proteins 
were used as a surrogate marker of MSI status. Results for 
MLH1, MSH2, MSH6 and PMS2 were available from 230 
KCCH GCs, and MLH1 and MSH2 from 253 LTHT GCs 
from a previous study [17]. MLH1, MSH2, MSH6 and 
PMS2 immunohistochemistry was performed on additional 
13 GCs from the KCCH cohort for this study, as previously 
described [17].
In TCGA, MSI was determined by a DNA based 
MSI-Mono-Derived-Dinucleotide Assay using four mononu-
cleotide repeat loci and three dinucleotide repeat loci using a 
multiplex fluorescent-labeled PCR and capillary electropho-
resis [29]. Results were obtained from the TCGA database 
portal [19] for 295 GC patients. MSI-low GCs were grouped 
with microsatellite stable (MSS) GCs for further analyses 
following current guidelines [33].
In the TMGH cohort, mononucleotide repeats BAT25 and 
BAT26 were investigated, as previously described [34–36] 
and GC were classified as MSS or MSI.
Statistical analyses
All statistical analyses were performed using SPSS soft-
ware version 23 (SPSS Inc., Chicago, III). The relationship 
between KRASmut or KRASamp and clinicopathological 
variables (age, gender, depth of invasion (pT), lymph node 
status (pN), TNM stage, Lauren classification [22], JGCA 
classification [21], MSI status and morphological hetero-
geneity status) was assessed using Chi-squared or Fisher’s 
exact test. The relationship between KRASmut and survival 
in LTHT and KCCH cohorts has been published previ-
ously [17]. Combining all cohorts, the relationship between 
KRASmut or KRASamp and 5-year overall survival was ana-
lysed using the Kaplan–Meier method and differences were 
assessed using the log rank test. A p value of < 0.05 was 
considered significant.
Results
Patient characteristics
The median (range) age of GC patients was as fol-
lows; KCCH: 65  years (35–85  years), LTHT: 72  years 
(14–96 years), TCGA: 68 years (35–90 years), TMGH: 
78 years (51–96 years). For a summary of other patient clin-
icopathological variables in each cohort see Table 2.
Histological classification of gastric cancer
Histological classification was available for 1271 GCs. 
Using the JGCA classification, the most predominant pheno-
type was moderately differentiated tubular  [tub2] (n = 408, 
32%), followed by poorly differentiated solid type [por1] 
(n = 229, 18%), poorly differentiated non-solid type [por2] 
(n = 227, 18%), well-differentiated tubular [tub1] (n = 219, 
17%), papillary [pap] (n = 71, 6%), signet-ring cell [sig] 
(n = 66, 5%) and mucinous [muc] (n = 51, 4%). According 
to Lauren classification, 293 (23%) GCs were classified as 
diffuse type, 698 (55%) as intestinal type, 51 (4%) as muci-
nous and 229 (18%) as indeterminate. Seven hundred and 
twenty-four GCs (57%) had intratumour morphological het-
erogeneity (see Table 2).
KRAS mutation status and relationship 
with clinicopathological variables
KRASmut status was available from 1266 GCs (KCCH 
n = 242; LTHT n = 275; TCGA n = 289, TMGH n = 460). 
In total, 68 (5%) GCs were KRAS mutant, with the highest 
frequency of KRASmut in the TCGA cohort (10%) and low-
est frequency in the TMGH cohort (3%), see Table 2. Within 
the KRASmut GC, the most frequent histological phenotype 
was intestinal type (n = 41, 61%) or tub2 (n = 27, 40%) by 
Lauren and JGCA classification, respectively (see Fig. 1a). 
Comparing individual histological subtypes, mucinous 
phenotype displayed the highest frequency of KRASmut 
by Lauren (p = 0.013) and JGCA (p = 0.012) classification, 
respectively (see Fig. 1b). KRASmut was more frequent in 
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Table 2  Comparison of clinicopathological variables in each gastric cancer cohort
Some variables do not add up to 1282 due to missing data
JGCA Japanese Gastric Cancer Association, Pap papillary adenocarcinoma, Tub1 well-differentiated tubular adenocarcinoma, Tub2 moder-
ately differentiated tubular adenocarcinoma, Por1 poorly differentiated adenocarcinoma solid type, Por2 poorly differentiated adenocarcinoma 
non-solid type, Sig signet-ring cell carcinoma, Muc mucinous adenocarcinoma, MSI microsatellite instable, MSS microsatellite stable, KCCH 
Kanagawa Cancer Center Hospital, LTHT Leeds Teaching Hospital Trust, TCGA The Cancer Genome Atlas, TMGH Tokyo Metropolitan Geri-
atric Hospital and Institute of Gerontology
Total (n)
1282
Total 
(%)
KCCH (n)
250
KCCH (%)
20
LTHT (n)
277
LTHT (%)
22
TCGA (n)
295
TCGA (%)
23
TMGH (n)
460
TMGH (%)
36
Age (years)
 < 65 343 27 122 49 78 28 123 42 20 4
 ≥ 65 936 73 128 51 199 72 169 58 440 96
Gender
 Male 769 60 175 70 164 59 182 62 248 54
 Female 513 40 75 30 113 41 113 38 212 46
T stage
 pT1 272 21 6 2 20 7 11 4 235 51
 pT2 138 11 43 17 24 9 44 15 27 6
 pT3 350 28 34 14 79 29 155 54 82 18
 pT4 512 40 167 67 154 56 75 26 116 25
N stage
 pN0 489 39 42 17 87 31 97 34 263 57
 pN1 247 19 58 23 52 19 64 23 73 16
 pN2 229 18 67 27 54 20 58 20 50 11
 pN3 306 24 83 33 84 30 65 23 74 16
TNM stage
 I 307 24 0 34 12 32 12 241 53
 II 384 30 97 39 81 29 116 42 90 20
 III 507 40 153 61 151 55 111 40 92 20
 IV 67 5 0 11 4 20 7 36 8
Lauren classification
 Diffuse 293 23 83 34 60 22 73 25 77 17
 Intestinal 698 55 103 42 145 54 156 53 294 64
 Mucinous 51 4 10 4 10 4 20 7 11 2
 Indeterminate 229 18 51 21 56 21 44 15 78 17
JGCA classification
 Pap 71 6 5 2 9 3 17 6 40 9
 Tub1 219 17 18 7 55 20 23 8 123 27
 Tub2 408 32 80 32 81 30 116 40 131 29
 Por1 229 18 51 21 56 21 44 15 78 17
 Por2 227 18 63 26 52 19 71 24 41 9
 Sig 66 5 20 8 8 3 2 1 36 8
 Muc 51 4 10 4 10 4 20 7 11 2
Morphological heterogeneity
 Homogenous 542 43 102 42 82 30 185 63 173 38
 Heterogeneous 724 57 140 58 189 70 108 37 287 62
KRAS mutation status
 Mutant 68 5 10 4 16 6 28 10 14 3
 Wild type 1198 95 232 96 259 94 261 90 446 97
KRAS gene copy number
 Amplified 47 7 12 6 17 8 18 8  -  -
 Other 602 93 196 94 199 92 207 92  -  -
Microsatellite instability status
 MSI 199 16 23 9 31 12 64 22 81 18
 MSS 1057 84 223 91 224 88 231 78 379 82
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MSI GC (p < 0.001). For the comparison of KRASmut status 
and other clinicopathological variables, see Table 3. The 
5-year overall survival rate in patients with KRASmut or 
KRAS wild type GC was 63.6% and 54.8%, respectively, 
p = 0.541, see Fig. 2a.  
KRAS amplification and relationship 
with clinicopathological variables
KRAS gene copy number status was available from 649 GCs 
(KCCH n = 208, LTHT n = 216, TCGA n = 225). In total, 47 
(7%) GCs had a KRASamp [TCGA (8%), LTHT (8%) and 
KCCH (6%)], see Table 2. Within KRASamp GC, intesti-
nal type (n = 23, 50% or tub2 (n = 21, 46%) was the most 
frequent histological phenotype by Lauren and JGCA clas-
sification, respectively (see Fig. 3a). Comparing individual 
histological subtypes, KRASamp was more frequently found 
in indeterminate type (n = 12, 10%) or por1 (n = 12, 10%) 
phenotype by Lauren and JGCA classification, respectively 
(see Fig. 3b). There was no relationship between KRASamp 
and histological phenotype or any other clinicopathological 
variables, see Table 4. The 5-year overall survival rate in 
GC patients with and without KRASamp was 47.6% versus 
55.6%, respectively, p = 0.166, see Fig. 2b. 
Only two GCs from the TCGA cohort had a concurrent 
KRASamp and KRASmut; one was a mucinous GC, the other 
was a por2 GC according to JGCA classification.
Discussion
This is the largest multicentre study to date to investigate 
the relationship between KRAS activation by mutation and/
or amplification and histological phenotype in GC. The fre-
quency of KRASamp (7%) was slightly higher than that of 
KRASmut (5%) which is consistent with other GC studies 
[10, 11, 37]. The higher frequency of KRASmut in the TCGA 
GC cohort compared to the other cohorts could be related 
to the methodology as TCGA used whole-exome sequenc-
ing to test non-hotspot regions, whereas other studies used 
less-sensitive Sanger sequencing/PCR–RFLP. We found 
KRASamp and KRASmut were exclusive in > 99% of GC, 
which is consistent with previous reports [11–13, 38].
The relationship between KRASmut and histological phe-
notype has not been investigated in great detail and previ-
ous studies were limited by small sample sizes and hence 
lack of statistical power [6]. In our study, we identified a 
relationship between KRASmut and mucinous histological 
phenotype, which is concordant with higher frequencies of 
KRASmut being reported in mucinous lung [8], ovarian [9] 
and colorectal cancer [39, 40]. However, due to the rela-
tively low frequency of GC with mucinous phenotype and 
KRASmut (12%), it would not be feasible to use the presence 
of a mucinous phenotype as a predictor for the presence of 
a KRASmut in GC. The main component of mucinous GCs 
is extracellular mucin, which consists of high molecular 
weight glycoproteins regulated by expression of the MUC2, 
MUC5AC and MUC6 genes in humans [41]. In mouse 
models with constitutively activated KRAS in the stomach, 
irregular MUC4+ cells were found with abnormal mucins 
confirmed by Alcian-blue staining [42]. Interestingly, our 
study suggests a relationship between KRASmut and muci-
nous phenotype, which is characterised by extracellular 
mucin, but is not related to signet-ring cell type GC, which 
is characterised by intracellular mucin. Our study confirmed 
the relationship between KRASmut and the presence of MSI, 
which our group and others have described previously in a 
smaller GC cohort [43, 44].
The prognostic significance of KRASmut in GC remains 
controversial [6]. In our study, there was no association with 
the presence of KRASmut and survival. Interestingly, in lung 
and colorectal cancer, KRASmut has been associated with a 
poor prognosis [45, 46], whereas in ovarian cancer, KRAS-
mut has been associated with an improved prognosis [47].
The relationship between KRASamp and clinicopathologi-
cal variables, including histological phenotype in cancer is 
not well studied. In GC, we found no statistically significant 
relationship between KRASamp and histological phenotype, 
or any other clinicopathological variables. In contrast, oth-
ers found that the presence of KRASamp is associated with 
a poor prognosis in GC [3, 10, 12]. This difference might be 
due to case selection and methodology used.
Fig. 1  Example of 
KRAS mutated GC with a 
moderately differentiated 
tubular (tub2) phenotype and b 
mucinous (muc) phenotype
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In our study, we used the JGCA scheme for the histolog-
ical classification of GC and performed a conversion to the 
Lauren scheme, which is the most widely used histological 
classification system in Western countries [22]. Previous 
studies investigating the relationship between KRAS-
mut and histological phenotype performed classification 
according to the Lauren scheme [6], for which there is no 
separate category for mucinous GC. The relatively large 
number of GCs classified as indeterminate according to 
the Lauren scheme comes from conversion from the JGCA 
por1 histological phenotype. Direct classification accord-
ing to the Lauren scheme, would likely result in a higher 
proportion of GCs classified as either intestinal or diffuse.
In colorectal cancer, KRASmut is known to be an early 
event in the progression from normal colonic epithelial cell 
to adenoma, and finally to carcinoma [48]. The evidence of 
sequential development by accumulation of genetic alter-
ations, including KRASmut, is still controversial in GC 
[49–51]. We were unable to make any comments regarding 
the role of KRAS activation in gastric carcinogenesis in our 
cohort as we did not investigate precancerous lesions in 
the current study. However, evidence from mouse models 
suggest that KRASmut is one of the key molecular altera-
tions involved in the development of stomach dysplasia 
[52] and GC [53]. Based on the evidence from other cancer 
types that KRASmut influence the progression of a muci-
nous histological phenotype, we therefore speculate based 
on our results, that KRASmut in GC is an early event in 
GC development, whereas KRASamp is likely to be a late 
event occurring after the histological phenotype has been 
established. This would correspond with experiments in 
mice expressing oncogenic KRAS in combination with 
E-cadherin and p53 loss, which resulted in a rapid pro-
gression of GC compared to wild type mice [53].
Our study has some limitations. This is a retrospec-
tive study. Histological phenotyping was performed on a 
single slide. Given the high frequency of intra-tumoural 
morphological heterogeneity in this study and the previ-
ously reported intra-tumoural heterogeneity in KRASmut 
status in GC [54], the sensitivity of some of the techniques 
used in the current study may not be sufficient to detect 
KRAS activation in subclones of tumour cells. As we did 
not perform microdissection of tumour subregions, we 
cannot comment on KRAS status heterogeneity within the 
same tumour. Furthermore, we used different techniques 
for DNA extraction, KRASmut status analysis and MSI 
analysis in different cohorts included in the current study, 
each with differing sensitivities [55, 56].
In summary, we identified a relationship between 
KRASmut and mucinous histological phenotype in GC. 
The high level of intratumour morphological heterogeneity 
could reflect KRASmut heterogeneity, which may explain 
the failure of anti-EGFR therapy in GC.
Table 3  Comparison of clinicopathological variables and KRAS 
mutation status in all gastric cancer cohorts combined
Some variables do not add up to 1282 due to missing data
JGCA Japanese Gastric Cancer Association, Pap papillary adeno-
carcinoma, Tub1 well-differentiated tubular adenocarcinoma, Tub2 
moderately differentiated tubular adenocarcinoma, Por1 poorly differ-
entiated adenocarcinoma solid type, Por2 poorly differentiated adeno-
carcinoma non-solid type, Sig signet-ring cell carcinoma, Muc muci-
nous adenocarcinoma, MSI microsatellite instable, MSS microsatellite 
stable, M mutated, WT wild type
KRAS mutation status p value
M
n
M
%
WT
n
WT
%
Age (years)
 < 65 13 4 319 96 0.167
 ≥ 65 55 6 876 94
Gender
 Male 36 5 723 95 0.225
 Female 32 6 475 94
T stage
 pT1/pT2 20 5 388 95 0.639
 pT3/pT4 47 6 802 95
N stage
 pN0 31 6 455 94 0.158
 pN1–pN3 35 5 734 95
TNM stage
 I–II 35 5 651 95 0.756
 III–IV 31 6 533 95
Lauren classification
 Diffuse 7 2 283 98 0.013
 Intestinal 41 6 652 94
 Mucinous 6 12 43 88
 Indeterminate 13 6 215 94
JGCA classification
 Pap 7 10 64 90 0.012
 Tub1 7 3 212 97
 Tub2 27 7 376 93
 Por1 13 6 215 94
 Por2 6 3 219 97
 Sig 1 2 64 99
 Muc 6 12 43 88
Morphological heterogeneity
 Homogeneous 31 6 506 94 0.550
 Heterogeneous 36 5 683 95
Microsatellite instability status
 MSI 33 17 165 83 < 0.001
 MSS 32 3 1010 97
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Fig. 2  Kaplan–Meier plots showing probability of overall survival 
in GC patients stratified by KRAS gene activation status. a Kaplan–
Meier survival analysis showed no difference in survival when 
patients were stratified by KRAS mutation status. b Kaplan–Meier 
survival analysis showed no difference in survival when patients were 
stratified by KRAS amplification status
Fig. 3  Example of KRAS ampli-
fied GC with a moderately 
differentiated tubular (tub2) 
adenocarcinoma and b poorly 
differentiated solid-type  
(por1) adenocarcinoma
1201KRAS status is related to histological phenotype in gastric cancer: results from a large…
1 3
Acknowledgements The authors thank S. Kanari for technical 
assistance.
Funding This study was supported in part by the JSPS KAKENHI 
Grant numbers JP25460428 and JP16K08664 (TA). HG has received 
funding from The Pathological Society of Great Britain and Ireland, 
Yorkshire Cancer Research and Sasakawa Foundation UK. TY has 
received funding from Sasakawa Foundation UK and Kanagawa Stand-
ard Anti-cancer Therapy Support System (Japan).
Compliance with ethical standards 
Conflict of interest The authors have no conflicts of interest to declare.
Table 4  Comparison of 
clinicopathological variables 
and KRAS copy number status 
in KCCH, LTHT and TCGA 
gastric cancer cohorts combined
Some variables do not add up to 822 due to missing data
JGCA Japanese Gastric Cancer Association, Pap papillary adenocarcinoma, Tub1 well-differentiated tubu-
lar adenocarcinoma, Tub2 moderately differentiated tubular adenocarcinoma, Por1 poorly differentiated 
adenocarcinoma solid type, Por2 poorly differentiated adenocarcinoma non-solid type, Sig signet-ring cell 
carcinoma, Muc mucinous adenocarcinoma, MSI microsatellite instable, MSS microsatellite stable, KCCH 
Kanagawa Cancer Center Hospital, LTHT Leeds Teaching Hospital Trust, TCGA The Cancer Genome 
Atlas
KRAS 
amplified 
(n)
KRAS 
amplified 
(%)
KRAS other (n) KRAS other (%) p value
Age (years)
 < 65 21 8 235 92 0.462
 ≥ 65 26 7 364 93
Gender
 Male 29 7 383 93 0.792
 Female 18 8 219 92
T stage
 pT1/pT2 8 7 109 93 0.867
 pT3/pT4 38 7 484 93
N stage
 pN0 7 4 163 96 0.058
 pN1–pN3 40 9 428 92
TNM stage
 I–II 14 5 262 95 0.061
 III–IV 32 9 325 91
Lauren classification
 Diffuse 10 6 168 94 0.480
 Intestinal 23 7 298 93
 Mucinous 1 3 29 97
 Indeterminate 12 10 107 90
JGCA classification
 Pap 0 0 24 100 0.267
 Tub1 2 3 70 97
 Tub2 21 9 204 91
 Por1 12 10 107 90
 Por2 9 6 144 94
 Sig 1 4 24 96
 Muc 1 3 29 97
Morphological heterogeneity
 Homogeneous 19 6 282 94 0.437
 Heterogeneous 27 8 315 92
Microsatellite instability status
 MSI 3 3 90 97 0.093
 MSS 44 8 494 92
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